• Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients

  NCT07563608

  RecruitingObservationalUpdated May 4, 2026
• Idiopathic Pre-capillary Pulmonary Hypertension in ESKD Patients

  NCT02743091

  CompletedObservationalUpdated Apr 19, 2016
• Ventriculo-Arterial Coupling and Intra-Dialytic Changes in Hemodialysis Patients: Prognostic Insights

  NCT06622928

  Not yet recruitingObservationalUpdated Oct 2, 2024
• Hemodialysis-Induced Blood Pressure Change In End-Stage Renal Disease

  NCT04933006

  CompletedObservationalUpdated Feb 11, 2022
• Epidemiology And Risk Factors Of Intradialytic Hypotension In Maintenance Hemodialysis Patients

  NCT07545629

  CompletedObservationalUpdated Apr 22, 2026
• Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension

  NCT06409624

  Active, not recruitingObservationalUpdated Oct 6, 2025

ClinicalTrials.gov ID

NCT07676786

Lead Sponsor

Stefan LujinschiOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

30Estimated

Last Update Posted

Jun 30, 2026Actual

Start Date

Jul 1, 2026Estimated

Primary Completion Date

Feb 28, 2027Estimated

Completion Date

Mar 30, 2027Estimated

Official Title

Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis

Brief Summary

Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.

This prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.

In participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.

The study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.

Detailed Description

Pulmonary hypertension (PH), defined as mean pulmonary arterial pressure (mPAP) >20 mmHg, is increasingly recognized in patients with chronic kidney disease and is particularly prevalent in those with ESKD on maintenance HD.

Despite its prognostic importance, PH remains under-recognized and insufficiently characterized in HD patients. A major limitation of prior studies is the lack of standardized assessment of volume status, which significantly influences pulmonary pressures.

This prospective, multicenter cohort study aims to address this gap by evaluating PH after rigorous volume optimization. The study includes:

• A pretrial volume assessment phase (3 consecutive HD sessions)
• A structured volume correction phase (if needed)
• A main study cohort including only euvolemic patients
• An exploratory subgroup of patients with persistent hypervolemia

Euvolemia is defined using a multimodal approach including clinical examination, bioimpedance spectroscopy, inferior vena cava (IVC) diameter, interdialytic weight gain, blood pressure stability, and lung ultrasound criteria.

The primary objective is to determine the prevalence of PH in euvolemic HD patients. Secondary objectives include characterization of PH phenotypes and identification of clinical, dialysis-related, and echocardiographic predictors.

Right heart catheterization (RHC) is not mandated for all participants. In patients with echocardiographic findings suggestive of PHafter confirmation of euvolemia, RHC may be performed when clinically indicated and separately consented. When available, invasive hemodynamic data will be used to confirm PH and refine phenotype classification.

• Pulmonary Hypertension (PH)
• End Stage Kidney Disease (ESRD)
• Hemodialysis Patients
• Volume Overload
• Volume Assessment
• Hemodialysis

• Observational Assessment

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years.
• End-stage kidney disease on maintenance HD for ≥ 3 months.
• Stable clinical condition (no hospitalization in last 30 days).
• Able and willing to comply with study protocol.
• Provision of written informed consent

Exclusion Criteria:

• Moderate/severe left-sided valvular disease.
• Active pulmonary or cardiac decompensation.
• Persistent hypervolemia after completion of the volume assessment and correction phase
• Inability to undergo echocardiography or bioimpedance assessment.
• Acute infection or inflammatory condition at the time of enrollment.
• Inadequate echocardiographic window preventing reliable assessment

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Stefan LujinschiOTHER

Collaborators

Institutul Clinic FundeniOTHER

Carol Davila University of Medicine and PharmacyOTHER

Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. IliescuOTHER

stefanlujinschi@gmail.com+40728102643